Summary:
In older adults with sarcopenic obesity, TECAR therapy combined with β-hydroxy-β-methylbutyrate (HMB) supplementation significantly improved physical function, nutritional status, handgrip strength, and decreased both body mass and BMI compared to placebo, TECAR + placebo, and sham TECAR + HMB groups, though it was associated with no reported adverse effects.
| PICO | Description |
|---|---|
| Population | 140 older adults diagnosed with sarcopenic obesity according to Asian criteria, randomly assigned to four equal groups. |
| Intervention | TECAR (transfer energy capacitive and resistive therapy) combined with HMB (β-hydroxy-β-methylbutyrate) nutritional supplementation for 12 weeks. |
| Comparison | Three control groups: (A) placebo for both interventions, (B) TECAR + placebo, and (C) sham TECAR + HMB supplementation. |
| Outcome | Group D (TECAR + HMB) showed significant improvements in SPPB total score (from 6.29 ± 1.34 to 8.06 ± 1.51, P<0.001), MBI (increase of ~8.2 points), handgrip strength (+2.07 kg), reduced body mass (-4.83 kg), and decreased BMI (from 30.14 to 28.34 kg/m², P<0.001). Synergistic effects were confirmed for physical performance and BMI reduction (F=16.374 and F=14.328, respectively; P<0.001 for both). |
Source: Renjie Wang, et al. “Efficacy of Transfer Energy Capacitive and Resistive Therapy Combined With beta-Hydroxy-beta-Methylbutyrate Nutritional Supplementation in Older Adults With Sarcopenic Obesity.” Read article here.
